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Abstract
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC) disorders that can
be classified on the basis of genetic, clinical, phenotypic features. Genetic lesions such as JAK2
mutations and BCR-ABL translocation are often mutually exclusive in MPN patients and lead to
essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia,
respectively. Nevertheless, coexistence of these genetic aberrations in the same patient has been
reported. Whether these aberrations occur in the same stem cell or a different cell is unclear, but
an unstable genome in the HSCs seems to be the common antecedent. In an effort to characterize
the underlying genetic events that might contribute to the appearance of more than one MPN in a
patient, we studied neoplastic cells from patients with dual MPNs by next-generation sequencing.
We observed that most patients with two MPNs harbored mutations in genes known to contrib-
ute to clonal hematopoiesis through altered epigenetic regulation such as TET2, ASXL1/2, SRSF2,
and IDH2 at varying frequencies (1%–47%). In addition, we found that some patients also har-
bored oncogenic mutations in N/KRAS, TP53, BRAF, EZH2, and GNAS at low frequencies, which
probably represent clonal evolution. These findings support the hypothesis that hematopoietic
cells from MPN patients harbor multiple genetic aberrations, some of which can contribute to clo-
nal dominance. Acquiring mutations in JAK2/CALR/MPL or the BCR-ABL translocation probably
drive the oncogenic phenotype towards a specific MPN. Further, we propose that the acquisition
of BCR-ABL in these patients is frequently a secondary event resulting from an unstable genome.
1 | INTRODUCTION
Myeloproliferative neoplasms (MPNs) are characterized by an expan-
sion of one or more lineages of myeloid stem cells. According to the
WHO classification, there are eight different phenotypes of MPNs.1
Several lines of evidence suggest that genomic instability in the hema-
topoietic stem cell (HSC) leads to development of molecular lesions
that generate the myeloproliferative phenotype.2 However, the under-
lying cause of this genomic instability is not well understood. The pres-
ence of the BCR-ABL1 fusion gene leads to a chronic myeloid leukemia
(CML) phenotype, while mutations in the JAK2 gene are linked to
essential thrombocythemia (ET), polycythemia vera (PV), and myelofib-
rosis (MF). In addition, exclusive of JAK2, ET, and MF patients can har-
bor CALR or MPL mutations.3 These genetic aberrations result in
dysregulated tyrosine kinases that generate proliferative signals in the
disease-initiating cells. Since these molecular aberrations are usually
perceived as mutually exclusive,4 once one MPN is diagnosed, tests for
the other mutation/fusion are rarely performed.
Recently, several case studies have described either concomitant
CML and ET/PV/MF or emergence of one of these diseases in patients
previously diagnosed with another MPN.5–9 In two cases where CML
emerged after PV, the BCR-ABL translocation was suggested to be a
secondary event in the JAK2-mutated clone.7,8 However, others have
suggested the mutations may arise in two independent clones.10
Nevertheless, both these scenarios presuppose an unstable genome
that induces multiple changes in a stem cell or favors emergence of
other competing clones. In this study, we evaluated the molecular land-
scape of hematopoietic stem and progenitor cells from patients with
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coexistent CML and MF using next-generation sequencing (NGS)
methods.
2 | METHODS
2.1 | Patients and samples
Patients were diagnosed and treated at the University of Michigan
Health system. Criteria for diagnosis of CML and post-ET and post-PV
MF were based on the WHO classification.1 Samples from consenting
patients were obtained with approval from the institutional review
board of the University of Michigan. Bone marrow and peripheral
blood mononuclear cells were prepared by Ficoll density gradient cen-
trifugation. For samples that were sequenced, bone marrow mononu-
clear cells were CD34 enriched using CD34 magnetic microbeads
(Miltenyi Biotec, San Diego CA), or total bone marrow or peripheral
blood mononuclear cells were used for isolation of nucleic acids.
Matched buccal swabs were used as the source of normal control DNA
for each patient. Patients were identified throughout the study using
their study ID assigned during enrollment.
2.2 | Clinical data
Clinical characteristics of each consenting patient were extracted from
patient charts. Laboratory results (e.g., diagnostic molecular testing),
treatment timelines, and drug regimens were compiled from patient
charts. Most cases of CML were diagnosed based on classical karyo-
type and/or FISH. Quantitative molecular diagnosis of BCR-ABL-
positive CML to determine response was based on PCR-based testing
and was available from some patients for a few time points and the
data is presented in International Scale (IS) or as otherwise indicated.
Spleen size measurements were based on palpation unless otherwise
stated.
2.3 | Integrative high-throughput sequencing and
mutation calls
Nucleic acid preparation, sequencing library construction, and high-
throughput sequencing were performed using standard protocols in
our sequencing laboratory, which adheres to the Clinical Laboratory
Improvement Amendments. Paired-end whole-exome libraries from
tumor and matched normal DNA were prepared using the Agilent Sure-
Select human all exon v4 probes (Agilent Technologies, Santa Clara
CA). Transcriptome libraries were prepared from total RNA and cap-
tured by the Agilent SureSelect human all exon v4 probes.11 All the
libraries were sequenced using the Illumina HiSeq2500 (Illumina, San
Diego CA). Aligned exome and transcriptome sequences were analyzed
to detect putative somatic mutations, insertions and deletions (indels),
copy-number alterations, gene fusions, and gene expression as
described previously.12,13
COSMIC v 79 was interrogated using the Cancer Browser tool on
the COSMIC web application, http://cancer.sanger.ac.uk/cosmic/
browse/tissue.
3 | RESULTS
3.1 | Concomitant versus sequential diagnosis of dual
MPN phenotype
We identified eight patients with diagnosis of two different MPNs (one
being CML) during the course of their treatment or at initial diagnosis.
Clinical characteristics of the patients and their diagnosis criteria for
each disease are summarized in Table 1. In two of the patients, both dis-
eases were diagnosed concomitantly; in the other patients, the second
condition was diagnosed during treatment due to ongoing and complex
physical findings (splenomegaly), cytogenetic findings of the Philadel-
phia chromosome (Ph), and pathological findings in the bone marrow,
such as CML patient with dysmegakaryopoiesis indicating more than
one myeloproliferative disease. The time between the establishments of
the two diagnoses varied from 0 to 15 years. In addition to the patients
presented, we identified three other MF patients who had minimal lev-
els of BCR-ABL by PCR without hematological disease (data not
shown). The predominant diagnosis at presentation varied among the
eight patients. Patient (Pt) 1471 was under observation for ET, which
progressed to MF and exhibited a BCR-ABL translocation along with a
JAK2V617F mutation. Similarly, Pt2105 with post-ET MF was found to
have BCR-ABL translocation during testing prior to enrollment onto a
clinical trial. However, Pt1191 was Ph1ve and did not have a
JAK2V617F mutation at the time of CML diagnosis; however, after
achieving a major molecular response, the patient’s bone marrow
showed a fibrotic myeloid neoplasm with prominent large megakaryo-
cytes in clusters with sinusoidal dilation containing hematopoietic ele-
ments. The bone marrow findings, positive reticulin staining and
persistent splenic enlargement implicated an overlap diagnosis of MF,
which was eventually confirmed by the presence of the CALR mutation.
Overall, CML was the first MPN diagnosis in two patients, second diag-
nosis in four patients, and concurrent diagnosis in five patients (data not
shown for three) following low level BCR-ABL detection.
3.2 | Treatment paradigms for the dual disease
patients
Treatment was tailored to the clinically dominant disease in cases of
concomitant diagnosis; in the other cases treatment was adjusted to
address the second condition. The patients’ treatment timelines are
summarized in Figure 1A. Each patient’s response to the treatment, as
measured by spleen size, WBC count, and BCR-ABL levels, is summar-
ized in Figure 1B. An addition or change in therapy was warranted
when a patient did not respond to a treatment as indicated by an
increase in BCR-ABL transcripts, increase in WBCs, or persistence or
increase in splenomegaly. A few of the patients were switched to TKI
therapy for CML combined with a JAK inhibitor or another therapy for
MF, either given together (Pt2105, dosed with ruxolitinib and imatinib/
dasatinib every day) or in an alternating schedule (Pt1137, alternating
schedule of nilotinib 4 days on/1 day off, then ruxolitinib 8 days on/1
day off). Most of these patients demonstrated improved response and
safe tolerability with this regimen, potentially endorsing a new
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treatment paradigm for dual MPN patients, which can be tested in a
carefully designed clinical study.
3.3 | Integrative high throughput sequencing of
patient samples
We obtained bone marrow and/or peripheral blood samples from 7 of
the 8 patients described in this cohort and assessed all genomic altera-
tions in the stem and progenitor cells wherever possible (Table 2). A
sufficient number of HSPCs were enriched by CD34-positive selection
from 3 patients, and for the other 4 patients, total bone marrow or
peripheral blood mononuclear cells were sequenced. Samples were
subjected to integrative sequencing, which includes whole-exome
sequencing of the tumor and matched normal sample, transcriptome
sequencing, and whole-genome sequencing. The samples for sequenc-
ing were obtained at different time points during treatment and stage
of disease; therefore, some genetic aberrations at diagnosis were unde-
tectable (Table 2). Pt1191 had a BCR-ABL translocation at CML diag-
nosis, but achieved a major molecular response to dasatinib treatment,
which was supported by negative PCR results for BCR-ABL in the
sequencing sample (Figure 2B). CALR mutations in patients with post-
ET MF have only recently been reported,3 and routine testing was
unavailable when patients in this study were first diagnosed with an
MPN. Although CALR mutations were not initially detected in Pt2105
during active treatment and stable disease, a length-affecting mutation
in exon 9 of the CALR gene was later discovered once the patient’s
MF symptoms worsened. In most patients, the sequencing results con-
firmed the molecular diagnostics in the patient charts. For Pt1505, clin-
ical diagnostics did not identify the MPLY591N mutation detected by
NGS (10% frequency). The MPLY591N is an atypical weak gain-of-
function mutation that increases MPL signaling.14
In addition to validating clinical findings, NGS detected several
additional genetic aberrations in the patients with concomitant MPNs.
We found varying frequencies (1-47%) of mutations in genes involved
in epigenetic regulation, including TET2, ASXL1/2, IDH2, SRSF2, and
EZH2 (Table 2), which have known incidences in MF.15,16 The 4 (out
of 7) patients who harbored at least one of these gene mutations prob-
ably have a higher incidence of epigenetic modifications than the <14%
incidence in CML (COSMIC data, Supporting Information Table S2).
Some patients also harbored oncogenic mutations in N/KRAS, TP53,
and BRAF at frequencies varying from 0.5 to 39% (Table 2). The subclo-
nal frequencies of these mutations might indicate clonal evolution of the
disease. BRAF mutations found included V600E, a well-established gain-
FIGURE 1 Clinical timeline of dual MPN diagnosis, treatment, response and NGS sampling. A, Each line depicts the clinical course of one
patient. The bars below show the timeframe of treatment directed towards MF or CML. The diagnosis of MF or CML is shown by a vertical
arrow on the top of the timeline. The time point of NGS sample acquisition is also shown as a vertical arrow. B, Each line represents one patient
as in A, with the same time intervals. The treatment changes are shown as vertical arrows. Spleen size measurements as based on palpation in
cm below the right costal margin or CT scans where indicated by a CT superscript. WBC counts are represented as 1000 s of WBC/microL of
blood. BCR-ABL was measured by PCR and is presented in IS (superscript % indicates % BCR-ABL1/ABL1, where IS units were unavailable).
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of-function mutation, as well as G469V and D594E, which are two atypi-
cal mutations that like V600E, occur within the kinase domain. BRAF
D594E has been previously reported in CMML cases.17
We interrogated the COSMIC database to determine the genes
that have been previously reported in CML (including blastic phase
CML), ET, PV, and MF. The top 20 genes in CML and blastic phase
CML were compared to each of the top 20 genes from ET/PV/MF
(Figure 2). The common genes found to be mutated in these diseases
included the same epigenetic regulators we found mutated in our
patient set, namely TET2, ASXL1, IDH1/2, SRSF2, and EZH2. Outside
of ABL1 (47%–28%), genetic variations in CML occur infrequently. Fre-
quency of TP53 mutations increased from 4% in chronic-phase CML to
26% in blast-phase CML. In Ph1ve MPNs, TP53 variant frequency was
only 2%–6%, suggesting that TP53 variants are associated with
advanced disease and are not driver mutations in these diseases.
4 | DISCUSSION
This report of eight patients with coexistent ET/PV/MF and CML,
along with other reports in the literature underscore that the frequency
of this phenomenon is significant. Most often one MPN is diagnosed,
precluding further testing for other diseases. Lack of response to ther-
apy is often the reason for alternate/additional diagnoses. Here, we
describe the diagnosis and management of patients with coexistent
MPNs. The treatment was tailored to the patient’s clinical presentation
and tolerance to therapy, and guided by our experience.
We used a whole-genome sequencing approach to understand the
pathophysiology of the dual disease phenotype. Our observations sug-
gest that patients with concurrent MPNs acquire either simultaneous
or sequential mutations in the HSPC. We therefore propose two mod-
els to explain the development of concurrent MPNs at the cellular
TABLE 2 Driver gene mutations in dual disease patients identified by integrative high-throughput sequencing
Driver Gene Mutations
Patient
Time point
of sample Sample type
BCR-ABL1
Gene fusion
JAK2 (% Allele
frequency)
CALR (% Allele
frequency)
MPL (% Allele
frequency)
Other mutations
(variant, % Allele
frequency)
1471 5.5 yrs post
second Dx
BM (CD33/341) Positive V617F (87%) Negative Negative BRAF (V600E, 0.5%)
BRAF (G469V, 3%)
KRAS (A146V, 1.5%)
TP53 (C238Y, 1%)
NF1 (R2258a, 4%)
PIK3R3 (R105W, 6%)
ASXL1 (G645V, 4%)
KMT2C (N729D, 7%)
1191 1 yr post
second Dx
BMMCs Negativea Negative Negative Negative KMT2D (A1740T, 37%)
FLG (S2366T, 20%)
2105 2.5 yrs post
second Dx
BMMCs
and PBMCs
Positive Negative E364fs (32%) Negative –
1505 2 yrs post
second Dx
BM (CD33/341) Negativea V617F (94%) Negative Y591N (10%) TET2 (Splice donor,
E1268, 34%)
TET2 (S217fs, 23%)
SH2B3 (Y572fs, 3%)
1137 At second Dx PBMCs Negativea Negative Negative m515L (95%) NRAS (G12V, 39%)
SRSF2 (P95H, 47%)
IDH2 (R140W, 43%)
EZH2 (S695L, 22%)
ASXL1 (D457fs, 44%)
2158 At second Dx PBMCs Positive
(low level)
V617F (4%) Negative Negative BRAF (D594E, 1%)
ASXL1 (G658a, 1%)
ASXL2 (R614a, 2%)
1565 5mos post
second Dx
BM (CD33/341) Negativea 1540一E543
delinsMK
Negative Negative GNAS (R202H, 21%)
aDenotes negative finding for BCR-ABL1 fusion gene due to sample timing was when patient was in major molecular response.
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level: (1) two independent clones arise from genetically unstable HSPCs
and compete with each other and (2) an already mutated HSPC
acquires a “second hit”. Previous reports from patients with two MPNs
suggest that BCR-ABL1 and JAK2V617F can be present in the same
clone of cells or in distinct clones.6,7,9,10,18–21 In some patients (n54)
from our cohort, the NGS analysis did not detect a previously identified
BCR-ABL1 translocation because patients were in molecular remission
at the time of sampling. JAK2 or MPL mutations were detected in
these samples after the CML subclone was suppressed. The other
interpretation is that the JAK2 mutation precedes BCR-ABL1 translo-
cation and therefore JAK2 persisted after BCR-ABL1 eradication.
Therefore, our data suggest that genetic events that lead to ET/PV/MF
arise in the HSPC and CML is a result of a “second hit.”
The literature supports that genetic instability in HSPCs is a pre-
condition for MPN initiation. HSPCs from “healthy” individuals, who
have no overt disease, can acquire mutations in several genes that
might contribute to a preleukemic state, which over time could further
destabilize the genome and result in the disease phenotype.22,23 These
pre-leukemic genes in healthy individuals could provide a competitive
advantage to the HSPCs, thus resulting in clonal hematopoiesis. Muta-
tions in epigenetic regulators such as DNMT3A, TET2, and ASXL1
genes occur frequently in these individuals and in patients with MPNs
including MF/ET/PV.16,24,25 These epigenetic regulators might contrib-
ute to the instability of the HSPC genome.26,27 In our studies, muta-
tions in TET2 (n52) and ASXL1 (n53) were found in some patients
who were stable or in remission at the time of sampling. We did not
detect any DNMT3A mutations, which is consistent with the low fre-
quencies previously reported in MPNs.15 TET2 loss-of-function muta-
tions in MPNs can worsen the course of JAK2V617F-induced disease
and increase the proliferative state of HSCs.27 ASXL1 was found to be
mutated frequently in MF (36%) and rarely in ET and PV.25 The patho-
physiology of loss-of-function ASXL1 mutations is not clear, though
some reports have suggested that mutant ASXL1 can collaborate with
NRASG12D in promoting myeloid leukemogenesis in mice.26 Interest-
ingly, ASXL1 mutations along with KRAS or NRAS mutation were
found in 2 of the 7 patients with concomitant MPNs. Based on COS-
MIC data, TET2 loss-of-function (4%) and ASXL1 loss-of-function
(10%) mutations are rarely found in CML, and the biological signifi-
cance of these mutants in a Ph1 setting is not yet understood.24 The
relative high frequency of these mutations in our series suggests either
dominance of MF with later development of CML, or may explain the
presence of two diseases in the same patient.
Novel findings from this small data set include GNAS and BRAF
mutations. Although BRAF mutations are frequent in Langerhans cell
histiocytosis and hairy cell leukemia (HCL), they are not considered
driver mutations in any myeloid neoplasms.28 Expression of
BRAFV600E in murine HSPCs resulted in features consistent with HCL
in mice.29 In our study cohort, 2 of 7 patients had BRAF mutations
albeit at low frequency and probably due to clonal evolution. One
patient harbored a GNAS hotspot mutation at a relatively high fre-
quency (21%), and this mutation is reported in several gastrointestinal
tumors and endocrine tumors.30 The small sample size of this study
does not allow us to conclude whether these mutations are of signifi-
cance to the dual-disease phenotype.
In conclusion, this is the first report of whole-genome sequencing
to determine genomic changes that might contribute to the manifesta-
tion of more than one myeloid neoplasm in the same patient. Our data
affirms that HSCs accumulate multiple genetic variants, which is a hall-
mark of patients with hematological malignancies. Identification of one
genetic variant did not preclude the presence of another that could
drive a phenotypically distinct disease. The data also suggest that the
CML in these patients might be a secondary disease arising from
FIGURE 2 COSMIC query of the top 20 genes in CML and ET/PV/MF. A, Venn diagram showing overlap of genes in both disease
subtypes. B, List of genes represented in the circles in A
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underlying genetic instability. Therefore, treatment paradigms for these
unusual cases should be tailored to target more than one signaling
pathway to sustain remission and improve outcomes of patients.
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